Market Closed -
Hong Kong S.E.
04:09:05 2024-06-07 am EDT
|
5-day change
|
1st Jan Change
|
0.52
HKD
|
-1.89%
|
|
-3.70%
|
-20.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
7,867
|
6,533
|
11,251
|
7,828
|
5,512
|
4,563
|
-
|
Enterprise Value (EV)
1 |
7,867
|
6,533
|
11,251
|
7,828
|
5,512
|
4,563
|
4,563
|
P/E ratio
|
-2.86
x
|
13
x
|
27.5
x
|
-4.09
x
|
-114
x
|
49.2
x
|
12.3
x
|
Yield
|
2.05%
|
2.03%
|
1.08%
|
-
|
-
|
10.2%
|
10.2%
|
Capitalization / Revenue
|
2.73
x
|
2.65
x
|
3.42
x
|
-
|
2.96
x
|
1.67
x
|
1.43
x
|
EV / Revenue
|
2.73
x
|
2.65
x
|
3.42
x
|
-
|
2.96
x
|
1.67
x
|
1.43
x
|
EV / EBITDA
|
-
|
6.34
x
|
10.6
x
|
-
|
-35.8
x
|
-42.6
x
|
34.6
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
0.82
x
|
0.71
x
|
1.35
x
|
-
|
-
|
0.95
x
|
0.96
x
|
Nbr of stocks (in thousands)
|
9,465,682
|
9,465,682
|
9,329,999
|
9,329,999
|
9,329,999
|
9,281,566
|
-
|
Reference price
2 |
0.8311
|
0.6902
|
1.206
|
0.8390
|
0.5908
|
0.4916
|
0.4916
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/29/22
|
3/24/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2,887
|
2,464
|
3,291
|
-
|
1,861
|
2,733
|
3,186
|
EBITDA
1 |
-
|
1,031
|
1,065
|
-
|
-153.9
|
-107
|
132
|
EBIT
1 |
1,517
|
787.1
|
763.9
|
-
|
-193.2
|
-305
|
-74
|
Operating Margin
|
52.53%
|
31.94%
|
23.21%
|
-
|
-10.39%
|
-11.16%
|
-2.32%
|
Earnings before Tax (EBT)
1 |
-2,467
|
765.8
|
486
|
-
|
-161.3
|
-589
|
-385
|
Net income
1 |
-2,753
|
473.4
|
416.5
|
-1,915
|
-54.02
|
107
|
337
|
Net margin
|
-95.37%
|
19.21%
|
12.65%
|
-
|
-2.9%
|
3.92%
|
10.58%
|
EPS
2 |
-0.2910
|
0.0530
|
0.0439
|
-0.2052
|
-0.005200
|
0.0100
|
0.0400
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0170
|
0.0140
|
0.0130
|
-
|
-
|
0.0500
|
0.0500
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/29/22
|
3/24/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-24.9%
|
5.04%
|
4.77%
|
-
|
-
|
2.3%
|
6.7%
|
ROA (Net income/ Total Assets)
|
-19.7%
|
3.7%
|
3.03%
|
-
|
-
|
0.9%
|
2.7%
|
Assets
1 |
14,007
|
12,808
|
13,769
|
-
|
-
|
11,889
|
12,481
|
Book Value Per Share
2 |
1.010
|
0.9700
|
0.8900
|
-
|
-
|
0.5200
|
0.5100
|
Cash Flow per Share
2 |
0.1500
|
-
|
0.0700
|
-
|
-
|
0.0400
|
0.0700
|
Capex
1 |
590
|
581
|
767
|
-
|
-
|
350
|
350
|
Capex / Sales
|
20.43%
|
23.56%
|
23.32%
|
-
|
-
|
12.81%
|
10.99%
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/29/22
|
3/24/23
|
3/28/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -20.00% | 630M | | +43.64% | 754B | | +40.52% | 630B | | -6.58% | 352B | | +19.72% | 331B | | +8.78% | 298B | | +18.52% | 250B | | +12.38% | 217B | | -0.25% | 216B | | +6.13% | 164B |
Other Pharmaceuticals
|